within Pharmacolibrary.Drugs.ATC.G;

model G02CB06
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.2,
    Cl             = 0.00025,
    adminDuration  = 600,
    adminMass      = 1 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.005,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0008333333333333334,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>G02CB06</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Terguride is a synthetic ergoline derivative with partial dopamine D2 receptor agonist and antagonist activity. It was under investigation for treatment of hyperprolactinemia, Parkinson's disease, and other prolactin-related disorders, but it is not currently marketed or approved for therapeutic use.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters in healthy adults based on related ergoline derivatives, as no direct human PK studies or published reports for terguride could be identified.</p><h4>References</h4><ol><li><p>Krause, W, et al., &amp; Dorow, R (1990). Pharmacokinetics and endocrine effects of terguride in healthy subjects. <i>European journal of clinical pharmacology</i> 38(6) 609–615. DOI:<a href=&quot;https://doi.org/10.1007/BF00278591&quot;>10.1007/BF00278591</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2373136/&quot;>https://pubmed.ncbi.nlm.nih.gov/2373136</a></p></li><li><p>Lapka, R, et al., &amp; Franc, Z (1986). Pharmacokinetics of oral terguride in patients with a prolactinoma. <i>European journal of clinical pharmacology</i> 30(3) 363–365. DOI:<a href=&quot;https://doi.org/10.1007/BF00541546&quot;>10.1007/BF00541546</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3732377/&quot;>https://pubmed.ncbi.nlm.nih.gov/3732377</a></p></li><li><p>Krause, W, &amp; Hümpel, M (1988). Pharmacokinetics of the dopamine partial agonist, terguride, in the rat and rhesus monkey. <i>European journal of drug metabolism and pharmacokinetics</i> 13(3) 185–194. DOI:<a href=&quot;https://doi.org/10.1007/BF03189938&quot;>10.1007/BF03189938</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/3240764/&quot;>https://pubmed.ncbi.nlm.nih.gov/3240764</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end G02CB06;
